1. Home
  2. ZYME vs TCBK Comparison

ZYME vs TCBK Comparison

Compare ZYME & TCBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZYME
  • TCBK
  • Stock Information
  • Founded
  • ZYME 2003
  • TCBK 1975
  • Country
  • ZYME United States
  • TCBK United States
  • Employees
  • ZYME N/A
  • TCBK N/A
  • Industry
  • ZYME Biotechnology: Pharmaceutical Preparations
  • TCBK Major Banks
  • Sector
  • ZYME Health Care
  • TCBK Finance
  • Exchange
  • ZYME Nasdaq
  • TCBK Nasdaq
  • Market Cap
  • ZYME 1.2B
  • TCBK 1.4B
  • IPO Year
  • ZYME 2017
  • TCBK N/A
  • Fundamental
  • Price
  • ZYME $18.08
  • TCBK $42.47
  • Analyst Decision
  • ZYME Strong Buy
  • TCBK Buy
  • Analyst Count
  • ZYME 8
  • TCBK 5
  • Target Price
  • ZYME $24.00
  • TCBK $47.60
  • AVG Volume (30 Days)
  • ZYME 668.9K
  • TCBK 78.8K
  • Earning Date
  • ZYME 11-06-2025
  • TCBK 10-24-2025
  • Dividend Yield
  • ZYME N/A
  • TCBK 3.50%
  • EPS Growth
  • ZYME N/A
  • TCBK N/A
  • EPS
  • ZYME N/A
  • TCBK 3.39
  • Revenue
  • ZYME $122,867,000.00
  • TCBK $391,277,000.00
  • Revenue This Year
  • ZYME $107.76
  • TCBK $9.45
  • Revenue Next Year
  • ZYME $2.35
  • TCBK $5.81
  • P/E Ratio
  • ZYME N/A
  • TCBK $12.14
  • Revenue Growth
  • ZYME 95.94
  • TCBK 0.78
  • 52 Week Low
  • ZYME $9.03
  • TCBK $35.20
  • 52 Week High
  • ZYME $19.50
  • TCBK $51.06
  • Technical
  • Relative Strength Index (RSI)
  • ZYME 65.50
  • TCBK 45.37
  • Support Level
  • ZYME $18.21
  • TCBK $40.44
  • Resistance Level
  • ZYME $19.10
  • TCBK $44.08
  • Average True Range (ATR)
  • ZYME 0.69
  • TCBK 1.03
  • MACD
  • ZYME 0.02
  • TCBK -0.18
  • Stochastic Oscillator
  • ZYME 56.97
  • TCBK 44.81

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

About TCBK TriCo Bancshares

TriCo Bancshares is a California corporation organized to act as a bank holding company for Tri Counties Bank. The Bank is a California-chartered bank that is engaged in the general commercial and retail banking business in California counties. The Bank provides a breadth of personal, small business, and commercial financial services, including accepting demand, savings and time deposits and making small business, commercial, real estate, and consumer loans, as well as a range of treasury management services and other customary banking services including safe deposit boxes at some branches. The company's primary source of revenue is the net interest income.

Share on Social Networks: